Vebreltinib
As of the edition of 20 October 2026, Vebreltinib is a small molecule: in active development; acts on MET.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 24, 1 stopped early
- Disease areas
- Cancer; Lungs and airways; Digestive system; Nervous system; Pregnancy and women's health; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MET | Hepatocyte growth factor receptor | P08581 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 4 | 3 | 0 | 0 |
| Phase 2 | 16 | 1 | 14 | 1 |
| Phase 3 | 4 | 0 | 4 | 0 |
| All trials | 24 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Pearl Biotechnology Limited Liability | Lead sponsor of trials | 2016 to now |
| Apollomics | Lead sponsor of trials | 2017 to now |
| Avistone Biotechnology | Lead sponsor of trials | 2023 to now |
| Ceres Brain Therapeutics | Lead sponsor of trials | 2025 to now |